(2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

(2004) A Novel Synthetic, Nonpsychoactive Cannabinoid Acid (HU-320) with Antiinflammatory Properties in Murine Collagen-Induced Arthritis

(2004) Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw

(2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. 

(2011) The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55

(2014) High hopes for cannabinoid agonists in the treatment of rheumatic diseases

(2015) Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis

(2015) Cannabinoid-based drugs targeting CB 1 and TRPV1 , the sympathetic nervous system , and arthritis

(2015) HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid

(2015) The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. 

(2015) The endocannabinoid system and its therapeutic implications in rheumatoid arthritis

(2016) Autoimmunity Reviews Cannabinoids and autoimmune diseases : A systematic review

(2016) Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials.

(2016) Neuropeptides Endocannabinoids inhibit neurogenic in fl ammation in murine joints by a non-canonical cannabinoid receptor mechanism

(2016) Survey of herbal cannabis ( marijuana ) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis

(2016) The synthetic cannabinoid WIN55 , 212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB 2 , TRPV1 , TRPA1 and yet unidentified receptor targets

(2016) Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis